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Candidate gene approachesNon-alcoholic fatty liver disease (NAFLD) is themost predominant liver diseaseworldwide and hepaticmanifes-
tation of the metabolic syndrome. Its histology spectrum ranges from steatosis, to steatohepatitis (NASH) that
can further progress to cirrhosis and hepatocellular carcinoma (HCC). The increasing incidence of NAFLD has
contributed to rising numbers of HCC occurrences. NAFLD progression is governed by genetic susceptibility, en-
vironmental factors, lifestyle and features of the metabolic syndrome, many of which overlap with HCC. Gene
expression proﬁling and genomewide association studies have identiﬁed novel disease pathways and polymor-
phisms in genes that may be potential biomarkers of NAFLD progression. However, the multifactorial nature of
NAFLD and the limited number of sufﬁciently powered studies are among the current limitations for validated
biomarkers of clinical utility. Further studies incorporating the links between circadian regulation and hepatic
metabolismmight represent an additional direction in the search for predictive biomarkers of liver disease pro-
gression and treatment outcomes.
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Non-alcoholic fatty liver disease (NAFLD) is awidely prevalent hepatic
metabolic disorder affecting up to 35% of western populations (Fig. 1),
with an even higher risk in individuals with obesity and type 2 diabetes
(T2D) [1–3]. NAFLD patients display a broad range of progressive stages
including the relatively benign steatosis, inﬂammation- and oxidative
stress-induced non-alcoholic steatohepatitis (NASH), ﬁbrosis and ulti-
mately, hepatocellular carcinoma (HCC). The poor understanding of
NAFLD pathogenesis stems from its complex nature, governed by
close interactions between genetic factors and environmental cues.
Recent studies have indicated the role of NAFLD as an emergingmenace
in triggering HCC [4], which is the ﬁfth most frequently diagnosed can-
cer worldwide and the third leading cause of cancer deaths [5]. 70–85%
of all diagnosed liver cancers are represented by HCC [6] whose rising
incidence has been witnessed in many developed countries [7]. While
hepatitis virus B and C (HBV/HCV) infections remain major risk factors
worldwide for HCC, a growing body of evidence clearly associates obe-
sity, T2D, alcohol and tobacco abusewith HCC risk, at least in the United
States [7,8]. A recent German study identiﬁed steatohepatitis as the un-
derlying aetiology of HCC in 24% of patients compared to 23.3% with
chronic HCV infection [9]. In addition to the development of HCC from
advanced forms of NAFLD, steatosis has also been implicated in the
development of HCC from cryptogenic cirrhosis [6] as well as
non-cirrhotic livers [10]. Thus, the proportion of NAFLD patients at
risk of developing HCC may be much higher than estimated to date,
highlighting the importance of the elucidation of molecular pathways
involved in the pathogenesis of NAFLD and malignant transformation
to HCC.
1.1. NAFLD pathogenesis
The accumulation of triglycerides in the liver (>5% of steatotic
cells in a liver section) is a histological hallmark of hepatic steatosis
[11,12]. Patients diagnosed with NAFLD in the absence of other hepatic
disease aetiologies or excessive alcohol consumption also display lobu-
lar inﬂammation, mild portal inﬂammation [13] and elevated levels of
alanine aminotransferase (ALT) in addition to hepatic steatosis [14].Steatosis
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Fig. 1. Relationship between NAFLD and HCC. NAFLD development is closely linked to
diabetes and obesity and is highly prevalent in patients with these metabolic dysfunc-
tions. NAFLD may primarily manifest as steatosis, steatohepatitis or cirrhosis due to
obesity-related metabolic complications or may progress through these stages over
several decades. Recent evidence indicates that HCC can develop from any stage of
NAFLD, however, with different likelihoods. While HBV and HCV infections remain
the major risk factors for HCC development, NAFLD-related HCC will become an even
more important risk factor in the near future due to the increasing prevalence of
NAFLD. Hh — hedgehog signalling pathway.Isotopic studies in liver biopsies from obese, hypertriglyceridemic and
hyperinsulinemic NAFLD patients have revealed elevated levels of
adipose-derived free fatty acid ﬂux and de novo lipogenesis [15], along
with compromised fatty acid oxidation and secretion [16].
The modulated expression and/or secretion of transcription factors
and cytokines respectively, inﬂuences downstream metabolic pathways
and thus, plays a crucial role in NAFLD pathogenesis (Fig. 2). For example,
sterol regulatory element-binding protein 1c (SREBP-1c/SREBF1) controls
the expression of lipogenic genes. Elevated SREBP-1c correlates with he-
patic steatosis in NAFLD patients [17]. The absence of carbohydrate-
response element binding protein (ChREBP/MLXIPL) that regulates
glucosemetabolismand lipogenesis improves hepatic steatosis, indicat-
ing that ChREBP is also linked to NAFLD [18]. Similarly, various PPAR
subtypes are linked to the pathogenesis of NAFLD [19]. Apart from
transcription factors involved in endogenous lipidmetabolism, nuclear
receptors regulating xenobiotic metabolism such as pregnane X recep-
tor (PXR/NR1I2) and constitutive androstane receptor (CAR/NR1I3)
and phase I and II drugmetabolizing enzymes also have altered proﬁles
in NAFLD patients. The cross-talk between hepatic lipid and drug
metabolism and its impact on the development of NAFLD has been
reviewed in detail recently [20].
While the progression of benign steatosis is relatively low, about 2–5%
of the general population progresses to NASH [3] (Fig. 1). Obesity
(BMI > 30 kg/m2) increases the risk of NAFLD progression with a preva-
lence of >25% of NASH patients among obese populations [2]. NASH is
characterised by a steatotic histology, severe lobular inﬂammation and
hepatocellular injury, such as the presence of ballooning, apoptosis or ne-
crosis [13]. The progression from NAFLD to NASH results from at least 2
hits (Fig. 2): the accumulation of triglycerides in the liver and the activa-
tion of inﬂammatory, oxidative stress and ﬁbrogenesis pathways [21,22],
along with free fatty acid lipotoxicity [23,24]. Apart from lipotoxicity due
to the accumulation of fatty acids, ceramide and cholesterol are also
crucial mediators of hepatic lipotoxicity [25]. The transcription factor
SREBP2(SREBF2) that regulates cholesterol synthesis is elevated in
hyperinsulinemia, which results in cholesterol accumulation, higher
levels of low-density lipoprotein receptor (LDLR) and reduced efﬂux of
free cholesterol into the bile, thus cumulatively contributing to the pro-
gression of NAFLD to NASH [26,27]. NASH patients have elevated
expression of genes involved in stellate cell activation and ﬁbrogenesis
and downregulated expression of survival genes [28]. Oxidative stress
due to reactive oxygen species (ROS) resulting from mitochondrial dys-
function, peroxisomal and microsomal fatty acid oxidation and lipid per-
oxidation is a hallmark of NASH. Liver injury resulting from chronic
exposure to drugs hampers themitochondrial role in fatty acid oxidation,
promotes steatosis and activates the cascade of ROS generation and sub-
sequent endoplasmic reticulum (ER) stress [20,25,29].
Among the cytokines, the adipose tissue secreted adipokines
(adiponectin and leptin) are linked to progression from NAFLD to
NASH. Adiponectin correlates negativelywith insulin resistance, plasma
triglycerides, LDL-cholesterol, hepatic fat content and progression to
NASH in NAFLD patients [30–32]. A deﬁciency of leptin causes hyper-
phagia, obesity and fatty liver, as shown in the ob/ob leptin-deﬁcient
mouse model. Leptin activates AMP-activated protein kinase (AMPK/
PRKAA2) in the skeletal muscle and the liver resulting in the enhance-
ment of fatty acid oxidation, hepatic glucose production and suppres-
sion of lipogenesis, thus improving NAFLD [33,34]. Levels of soluble
leptin receptor, which binds the circulating leptin, correlate with diabe-
tes, ﬁbrosis and NAFLD progression in morbidly obese patients [35].
Other adipokines, such as resistin (RETN), visfatin (NAMPT) and retinol
binding protein 4 (RBP4) also appear as promising potential NAFLD
mechanistic markers [36–39]. The cytokine tumour necrosis factor alpha
(TNF-α) is elevated in NASH patients compared to patients with benign
steatosis [40]. It activates the transcription of other pro-inﬂammatory
cytokines such as inhibitor of nuclear factor kappa-β (IKBKB) and
nuclear factor kappa-B (NF-κB) [41] and enzymes involved in de novo li-
pogenesis [42].
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Fig. 2. Molecular mediators involved in NAFLD pathogenesis.
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the proposed third hit in NAFLD progression, leading to an increased
population of hepatocyte progenitor cells and prolonged inﬁltration
of inﬂammatory mediators [43]. These events are catalytic to hepatic
ﬁbrosis, cirrhosis and eventually hepatocellular carcinoma (Fig. 2).
The presence of the metabolic syndrome and histological features of
NASH in cryptogenic cirrhosis patients implies the progression from
NASH to cirrhosis [44]. In addition, the development of HCC from NASH
coincided with the presence of cirrhosis in a Japanese population [45].
However, studies inmicewith obesity-related steatosis showhyperplasia
and reduced cell death even in the absence of cirrhosis [46]. Molecular
factors involved in obesity and diabetes establish a tumour-promoting
environment, which distinguishes the pathogenesis of NAFLD-related
HCC to that of viral or other aetiologies [47]. In obesity, the adipose tissueexpansion leads to increased release of pro-inﬂammatory cytokines
such as TNFα and interleukin-6 (IL6) that activate pro-oncogenic and
anti-apoptotic pathways [39,47]. Ectopic deposition of fat in hepatocytes
may alter gene expression proﬁles through deregulation of cell signalling
pathways and contribute to development of HCC [48]. Elevated levels of
peroxides and free radicals as a consequence of fatty acid oxidation can
cause oxidative injury, endoplasmic reticulum stress and apoptosis [49].
These events together promote liver inﬂammation and increase the risk
of developing HCC.
2. Omic approaches aid in understanding liver pathologies
A large number of high resolution omic studies in NAFLD patients
and animal models have contributed to novel insights into the
87A. Naik et al. / Genomics 102 (2013) 84–95molecular aspects of NAFLD [28,50,51]. Reverse-phase protein
microarrays indicated a deregulation of the insulin-receptor mediat-
ed molecular signalling in white adipose tissue of progressive
NAFLD patients [52]. Speciﬁc phosphorylation and biomarker (e.g.
caspase 9) signatures in omental fat could differentiate between
steatotic and NASH obese patients. Serum metabolomics has identi-
ﬁed a panel of biomarkers that can differentiate the NAFLD/NASH dis-
ease state from normal [53]. These ﬁndings are crucial in the search for
predictive non-invasive biomarkers as at present the liver biopsy is the
most accurate method to diagnose early progression stages from
steatosis to NASH. Recent advances in sequencing and expression pro-
ﬁling technologies, ﬁne mapping and functional analysis of genomes,
genome-wide association studies and applications of animal models,
along with initiatives such as the Human Genome Project, HapMap
and ENCODE, provided novel insights to dissect the pathogenesis of
NAFLD, as described further.
Male C57/BL6 mice that develop hepatic steatosis and obesity on
a high-fat diet displayed altered expression of 309 genes compared
to the control diet, including genes of the lipogenesis and fatty acid
oxidation pathways [50]. Rodents with orotic acid-induced steatosis
displayed altered expression of genes involved in fatty acid, lipopro-
tein and glucose metabolism and stress and inﬂammatory pathways
[54].
Transcriptomic analyses in patients with different stages of NAFLD
identiﬁed differential expression of hepatic and adipose genes at pro-
gressive stages of NAFLD [28,55]. While early stages of NAFLD were
accompanied by upregulation of cell survival and liver regeneration
genes and downregulation of defence mechanisms against oxidative
stress [28], NASH stages displayed upregulation of stellate cell activa-
tion, inﬂammation, ﬁbrogenesis and detoxiﬁcation pathways centred
around TNFα, IL6, JUN and interferon γ (IFNG) regulation. Additional-
ly, the survival factor ADP-ribosylation factor-like 6 interacting protein
(ARL6IP/RAMER) and phase II enzyme sulfotransferase 1A2 (SULT1A2)
were downregulated [28,55]. Gene expression analysis comparing
Caucasians, who have a higher risk of NAFLD, and African-Americans
indicated ethnic differences in gene expression patterns, especially
among NASH patients [56]. The most prominently upregulated genes
in African-Americans are glutathione s-transferases GSTM-2, -4, and -5,
acyl-CoA synthetase long-chain family member 4 (ACSL4), insulin-like
growth factor 2 (IGF2) and cytochrome p450 3A4 (CYP3A4) [56].
Additionally, epigenetic changes andmicro RNAs have been linked
to liver pathologies. A study comparing miRNA expression in NASH
patients against controls identiﬁed a signiﬁcant decrease in miR-122,
which may account for insulin resistance, oxidative stress, apoptosis
and inﬂammation in NASH [57]. miR-122 accounts for 70% of hepatic
miRNA and its inhibition in mice on a high-fat diet improved hepatic
steatosis, lowered plasma cholesterol and the expression of lipogenic
genes [58]. Other miRNAs such as miR-335, miR-181d and miR-10b
have been implicated in lipid homeostasis and adipocyte differentiation
[59].
2.1. Genetic associations with NAFLD and HCC
The heritability of NAFLD and its complex nature have triggered the
advent of several candidate gene studies and a few genome-wide asso-
ciation studies (GWAS) in NAFLD populations. Similarly, numerous
candidate-gene studies have reported associations between SNPs and
the presence of HCC, while limited GWAS studies have shed light into
additional unsuspected loci that might be involved in hepatic carcino-
genesis [60]. The variants identiﬁed in association with HCC and NAFLD
share some common molecular pathways such as oxidative stress, iron
metabolism, and inﬂammatory and immune response, suggesting that
gene variants associated with NAFLD could potentially modulate path-
ways involved in HCC and vice versa [60]. A comparison of SNPs curated
from NAFLD-related literature searches and those reviewed by Nahon et
al. [60] in the context of HCC, highlighted only 4 common SNPs: GSTM1and SOD2 A16V from the oxidative stress response pathway, TNF
G-238A involved in inﬂammatory/immune response and PNPLA3
I148M, which potentially has a lipolytic role. However, it is important
to note that the HCC variants described by Nahon et al. were discovered
in studies that compared normal controls to HBV- or HCV-infected pa-
tients or patientswith alcohol abuse. Studies designed to identify genetic
risks of NAFLD-triggeredHCC are limited and require amore focussed at-
tention in the future [4,61].
The most prominent genetic variations associated with NAFLD are
listed in Table 1. Below we provide a detailed overview of polymor-
phisms that have been associated with NAFLD. We begin by describ-
ing the four overlapping polymorphisms associated with NAFLD and
HCC in genes PNPLA3, SOD2, TNFα, and GSTM1, followed by other con-
tributing SNPs in genes involved in lipid metabolism, inﬂammatory
pathways, xenobiotic detoxiﬁcation, etc.
2.1.1. Patatin-like phospholipase domain containing 3 (PNPLA3)
PNPLA3 is one of the few examples that has been validated in sev-
eral populations and conclusively shown to associate with NAFLD.
Although the functional roles of PNPLA3, which encodes adiponutrin,
or its genetic variants have not been fully determined, it is known to
have lipase activity in vitro. The expression of PNPLA3 is regulated by
ChREBP and SREBP, implicating its function in glucose and lipid metab-
olism [62]. Surprisingly, Pnpla3 knock-out (KO) mice or mice with in-
creased Pnpla3 expression did not display lipolysis abnormalities or
hepatic steatosis [63]. The activation of compensatory mechanisms
that may involve other members of the Pnpla family was not observed
either. Hence, developing tissue-speciﬁc Pnpla3-overexpressionmodels
may be a more accurate approach to solve these inconsistencies.
PNPLA3was ﬁrst identiﬁed as a susceptibility gene in a large study
including Hispanics, African-Americans and European-Americans from
the Dallas Heart Study [64]. The rs738409[G] variant signiﬁcantly asso-
ciates with increased hepatic fat and inﬂammation whereas the
rs6006460[T] correlates with lower hepatic fat. This observation was
replicated in a Finnish study [65] and a recent large-scale GWAS study
genotyping 2.4 million SNPs in 7100 individuals as a meta-analysis
from several large population studies [66]. Moreover, studies in Italian,
Chinese, Indian, Malay, Japanese and United Kingdom populations indi-
cated that a homozygosity in the rs738409[G] variant predisposed
patients to NASH [67–69]. A study to determine if the NAFLD-associated
rs738409 variant in PNPLA3 also affects the prognosis of HCC in Japanese
patients concluded a higher incidence of the G/G genotype of rs738409
PNPLA3 in NAFLD-related HCC [70]. The genotype was associated with
higher BMI and severe ﬁbrosis but was found to affect HCC prognosis
only in the alcoholic liver disease patients' subgroup [70]. The G allele of
rs738409 PNPLA3was also over-represented in alcoholic/metabolic cir-
rhosis Italian patientswith HCC [71], in accordancewith Takeuchi et al.,
highlighting the potential predictive value of this polymorphism for
HCC occurrence in cirrhotic patients.
2.1.2. Manganese superoxide dismutase (MnSOD/SOD2)
As oxidative stress represents the second-hit in the development
of NASH, molecular mechanisms that lead to the generation of ROS
may contribute to NASH pathogenesis. SOD2 protects against ROS
by detoxifying superoxides into oxygen and hydrogen peroxide. The
1183 T/C polymorphism has been identiﬁed in the targeting sequence
that directs SOD2 to the mitochondria. The presence of TT genotype at
this position associates with NASH and with the degree of ﬁbrosis in
NAFLD patients, due to decreased transport of the protein into the mi-
tochondria [72]. This association was further conﬁrmed by familial
analysis using the transmission disequilibrium test in 55 informative
families and a case–control study in a larger European NAFLD popu-
lation [73], both with biopsy-proven NASH [60]. A prospective study in
alcoholic cirrhosis patients identiﬁed the presence of theAla16Val-SOD2
allele as a susceptibility factor for HCC development and death, with
further detrimental outcomes in combination with the G-463A
Table 1
Genetic associations implicated in the pathogenesis of NAFLD. *Genes that have also been highlighted in association with HCC.
Gene Protein function Association with NAFLD
Patatin-like phospholipase domain
containing 3 (PNPLA3)/adiponutrin *
• Lipolytic and lipogenic function in vitro
• Gene expression enhanced by SREBP-1c
• I148M SNP signiﬁcantly associated with hepatic fat content, ALT and AST
activities, ﬁbrosis and NASH. No correlation with insulin sensitivity observed
[55,56,58–60,136].
• S453I associated with decreased risk of hepatic triglyceride accumulation.
• Higher incidence of the G/G genotype of rs738409 PNPLA3 in NAFLD-related
HCC patients, associated with higher BMI and severe ﬁbrosis [63,64].
Superoxide dismutase 2 (SOD2) * • Detoxiﬁcation of mitochondrial ROS • T/T genotype in mitochondrial targeting sequence is signiﬁcantly prevalent
in NASH patients [65].
• Frequency of T allele in the mitochondrial targeting sequence is proportional
to the degree of ﬁbrosis in NAFLD patients [72].
• Ala16Val-SOD2 allele is a potential susceptibility factor for HCC
development and death in alcoholic cirrhosis patients, with further
detrimental outcomes in combination with the G-463A MPO variant [73].
Tumour necrosis factor-alpha (TNF) * • Pro-inﬂammatory cytokine • Higher prevalence of the TNFα-238 polymorphism but not the 308 polymorphism,
in NAFLD patients and was associated with increased insulin resistance
[69,104–106,109].
• Meta-analysis showed that TNFα-308G/A, TNFα-238G/A and TNFα-863C/A
polymorphisms may associate with HCC in Asians populations [110].
Glutathione S-transferase (GST) * • Phase II detoxiﬁcation enzyme
• Defence against oxidative stress
• GSTM1-null genotype present at a higher frequency in Japanese NAFLD
population [120].
• GSTM1-null genotype associates with increased HCC risk in Asians, with
further risk in the presence of dual GSTM1/GSTT1 null genotype [121].
Peroxisome proliferator-activated
receptor α (PPARA)
• Activates fatty acid oxidation and
hepatic lipid hydrolysis
• Ala227 PPARα variant is associated with lower fat indices in NAFLD patients
[98].
PPARα co-activator 1-α (PPARGC1A) • Transcriptional co-activator of PPARγ
• Regulates genes involved in energy
metabolism
• Deﬁciency results in enhanced lipogenesis and hepatic steatosis in mice [100].
• DNA methylation in PPARGC1A gene implicated in the degree of insulin resistance
in NAFLD [99] and rs2290602 SNP in the PPARGC1A gene associated with the
progression of NAFLD to NASH in patients [102].
Microsomal triglyceride transfer
protein (MTTP)
• Synthesis and secretion of VLDL in liver • -493 G/T SNP associated with NAFLD. GG homozygous patients have lower
MTTP activity, severe steatosis and more atherogenic postprandial lipid
proﬁle in NASH patients, independent of insulin resistance [65,67].
Phosphatidylethanolamine methyltransferase
(PEMT)
• Synthesis of phosphatidylcholine • V175M SNP confers susceptibility to NASH patients [68].
Apolipoprotein C-III (APOC3) • Inhibition of LPL • C482T and T455C variant carriers have 30% increased fasting plasma ApoC3
and 60% increased fasting plasma triglycerides [75].
• 38% of C482T and T455C variant carriers displayed NAFLD compared to none
in the WT allele subjects [75].
Apolipoprotein E (APOE) • Plasma lipid transport protein. • APOE-ε3 allele has a signiﬁcantly high incidence in NASH patients [81].
• APOE-ε2 allele may be protective against NAFLD [82].
Adiponectin (ADIPOQ) • Insulin-sensitizing, anti-inﬂammatory
adipokine.
• G45T and G276T in ADIPO occur at a higher incidence in an Italian NAFLD
cohort, however, contrasting observations made in Asian populations [88].
• ADIPOR2 rs767870 polymorphism is signiﬁcantly associated with a 50%
decrease in hepatic fat accumulation and decrease in serum γ-glutamyl
transferase and triglyceride concentrations in a Finnish cohort [90].
Insulin receptor substrate 1 (IRS1) • Downstream regulator of insulin action • Gly172Arg polymorphism affects insulin receptor activity and is signiﬁcantly
associated with NAFLD disease severity in Caucasian NAFLD patients [85].
Growth hormone (GH)/insulin-like
growth factor-1 (IGF-1)
• Stimulates growth, regulates fatty acid
oxidation, lipolysis, LDL clearance and
gluconeogenesis
• NAFLD is common in patients with adult growth hormone deﬁciency (AGHD).
• G allele of PPARγ, rs1800775, rs708272 and rs3764261 in CETP gene, T allele
of APOE SNP rs7412 and C allele of SNP rs35136575 in the APOE/C1/C4/C2
gene cluster associated with altered serum lipid proﬁles in severe AGHD
patients [132].
• IGF1 and IGFBP3 polymorphisms are potentially associated with NAFLD-related
changes in IGF-1 and IGFBP-3 proteins [133,134].
Interleukin-6 (IL6) • Pro-inﬂammatory cytokine • IL6-174C variant present at a higher frequency in NASH than in NAFLD patients
and accompanied by increased insulin resistance in a Caucasian cohort [115].
Pregnane X receptor (PXR/NR1I2) • Nuclear receptor • rs2461823[A] and rs7643645[G]- containing haplotypes in the PXR gene
associated with disease severity and liver injury in a European NAFLD
population [117].
UDP-glucuronosyltransferases 1A1 (UGT1A1) • Phase II detoxiﬁcation enzyme.
• Anti-oxidative stress
• UGT1A1*6 allele associated with a lower risk of NAFLD in an obese Taiwanese
cohort [118].
ABC- transporter ABCC2 • Xenobiotic transporter • SNPs rs17222723 and rs8187710 identiﬁed in association with NAFLD, liver
histology and disease severity [119].
Neurocan (NCAN) • Regulates cell adhesion and migration • rs2228603 SNP is associated with NAFLD and serum lipids [57].
Glucokinase regulator (GCKR) • Inhibits glycogen synthesis • rs780094 SNP is associated with NAFLD and serum lipids [57].
Lysophospholipase-like 1 (LYPLAL1) • Involved in triglyceride synthesis • rs12137855 SNP is associated with NAFLD and serum lipids [57].
Group-speciﬁc component (GC) • Vitamin D–binding protein • rs222054 SNP associated with NAFLD in an adolescent population [124].
• Expression reduced by 83% in NAFLD liver biopsies. Serum and protein levels
lower in progressive stages of NAFLD compared to controls [124].
Lymphocyte cytosolic protein 1 (LCP1) • Actin-binding protein • rs7324845 SNP associated with NAFLD in an adolescent population [124].
• Gene expression increases by 300% in NAFLD liver biopsies [124].
Lipid phosphatase-related protein
type 4 (LPPR4)
• Neuron-speciﬁc
• Dephosphorylates mediators in
neuron development
• rs12743824 SNP associated with NAFLD in an adolescent population [124].
Solute carrier family 38 member
8 (SLC38A8)
• Brain-speciﬁc putative sodium-coupled
neutral amino acid-transporter
• rs11864146 SNP associated with NAFLD in an adolescent population [124].
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sive hepatic iron accumulation associated with Ala16Val-SOD2, accom-
panied by increased ROS-related oxidative stress and DNA damage
caused by excessive MPO activity [74].
2.1.3. Tumour necrosis factor α (TNFα)
TNFα is a cytokine with broad functionality in inﬂammation, auto
immunity, tumour apoptosis and metabolic regulation [75]. Increased
levels of TNFα correlate with insulin resistance and the activation of
inﬂammatory pathways, thus increasing the risk of NAFLD progres-
sion to NASH [39,76]. Several polymorphisms have been identiﬁed
in the TNFα gene promoter [77]. Candidate gene studies in an Italian
population identiﬁed a higher prevalence of the TNFα-238 promoter
polymorphism but not the -308 polymorphism in NAFLD patients
compared to controls [78]. Despite impaired insulin sensitivity, the
-238 polymorphism was also associated with lower LDL-cholesterol,
and comparatively lower BMI, indicating an inverse effect on the reg-
ulation of glucose and lipid metabolism. Similar observations were
made in a Mexican and two separate Chinese cohorts that displayed
an association between TNFα-238 and NAFLD/NASH [79–81]. A study
in Japanese population identiﬁed two different polymorphisms in the
TNFα promoter, -1031C and -863A, that were present at a higher fre-
quency in NASH patients compared to patients with simple steatosis
[82]. The lack of association of the -238 and -308 polymorphisms in
the Japanese could be attributed to ethnic differences and the low fre-
quency of variations at these positions in this population. Although
other studies in Chinese populations failed to identify any of these asso-
ciations,mainly due to the lack of statistical power [83], ameta-analysis
of 8 studies evaluating polymorphisms in TNFα conﬁrmed the associa-
tion of the -238 polymorphismwithNAFLD, however the -308 polymor-
phism was not identiﬁed as a susceptibility factor [84].
Another recentmeta-analysis to assess the association between TNFα
polymorphisms and HCC susceptibility showed that TNFα-308G/A,
TNFα-238G/A and TNFα-863C/A polymorphisms may associate with
HCC in Asians populations [85]. This observation is biologically plausi-
ble in the context of tumour-promoting roles of TNFα in various can-
cer types [86].
2.1.4. Glutathione s-transferases (GST)
Glutathione s-transferases (GST) are phase II DMEs involved in
xenobiotic detoxiﬁcation and protection against oxidative stress. A
case–control analysis indicated that the GSTM1-null genotype was
present at a higher frequency in a Japanese NAFLD population [87].
A meta-analysis suggests that the null genotype of GSTM1 associates
with increased HCC risk in Asians. Individuals with the dual GSTM1/
GSTT1-null genotype have an even further susceptibility in developing
HCC [88]. The GSTM1/GSTT1-null genotype has also been identiﬁed in
association with several complex disorders featuring oxidative stress,
inﬂammatory and detoxiﬁcation irregularities, such as T2D [89], male
infertility [90], etc. Thus, it seems plausible that GST-null polymor-
phisms associate with characteristics such as oxidative stress and in-
ﬂammation, rather than with the disease in general.
2.1.5. Peroxisome-proliferator-activated receptor α (PPARα) signalling
PPARαplays amajor regulatory role in lipidmetabolismby activating
fatty acid oxidation and lipid hydrolysis, thus preventing hepatic lipid
accumulation [19,91]. Adiponectin has an indirect effect on PPARα
activation [92]. Mice fed a methionine-, choline-deﬁcient diet (MCD)
develop steatosis, which is improved on treatment with PPARα-
agonists [93]. Similarly, PPARα−/−mice develop hepatic steatosis on
a high fat diet [94]. Thus, PPARα-agonist ﬁbrates are used to treat
patients with elevated plasma triglycerides [95]. Several studies show
a correlation between the Val227Ala variant of PPARα and low serum
lipids [96,97]. A case–control comparison study of NAFLD patients
highlighted a potential protective role for the Val227Ala variant against
obesity. The subjects with the Ala227 variant appear to have lower fatrelated indices, although no signiﬁcant differences were identiﬁed in
serum glucose, triglyceride and cholesterol levels [98]. The functional
role of this SNP requires further elucidation.
PPARγ-coactivator 1-alpha (PGC1-α/PPARGC1A) is a systemic
modulator of energy homeostasis, a deﬁciency of which results in en-
hanced lipogenesis and hepatic steatosis in mice [99]. The regulation
of PGC1-α by sirtulin (SIRT1) and AMPK may possibly provide a
mechanism for its ability to sense metabolic deregulations [100]. Post-
translational modiﬁcations such as DNA methylation in the PGC1-α
gene associate with the degree of insulin resistance in NAFLD patients
and to the liver mitochondrial DNA content [101]. The T allele of the
SNP rs2290602 in PPARGC1A was present at a signiﬁcantly higher fre-
quency in NASH patients compared to patients with simple steatosis
andwas associated with decreased expression of the gene in a Japanese
biopsy-proven NAFLD population [102].
2.1.6. Microsomal triglyceride transfer protein (MTTP)
MTTP is involved in the formation of VLDL particles from triglycer-
ides and apolipoprotein B (ApoB). A study in rats has indicated a role
of DNA methylation of theMttp promoter which decreased the expres-
sion of Mttp gene on high fat diet [103]. The -493 G/T MTTP polymor-
phism occurred at a higher incidence in a Japanese NASH population
compared to healthy controls [72]. The G allele results in decreased
transcription of the MTTP gene and increased accumulation of triglycer-
ides in the liver. Furthermore, the degree of disease severity and plasma
lipid proﬁle correlated with the G/G genotype at -493 position of the
MTTP gene in a cohort of NASH patients, independent of the level of
adipokines and insulin resistance [104]. However, due to the small num-
ber of patients in this study these observations need to be replicated in
larger cohorts and different populations.
2.1.7. Phosphatidylethanolamine methyltransferase (PEMT)
PEMT contributes to the synthesis of phosphatidylcholine from
phosphatidylethanolamine. Phosphatidylcholine is an essential compo-
nent of VLDL formation for hepatic triglyceride secretion. Loss of function
of Pemt results in increased accumulation of lipids in mice [105]. The
V175M loss-of-function mutation in the human PEMT gene associates
with NAFLD patients [106]. This observation has been replicated in a
Chinese population [80]. Moreover, the presence of the polymorphism
may indicate susceptibility to NASH, as observed in a Japanese popula-
tion of NASH patients compared to healthy controls [107].
2.1.8. Apolipoprotein C-3 (ApoC3)
ApoC3, which is expressed in the liver, functions as an inhibitor of
lipoprotein lipase (LPL) that hydrolyses triglycerides in VLDL particles
and chylomicrons in the plasma. Its absence or over-expression re-
sults in hyper- or hypo-triglyceridemia, respectively. In mice, insulin
inhibits ApoC3 expression via the nuclear exclusion of FOXO1,
a transcription factor triggering the expression of ApoC3, which ex-
plains the aberrant apoC3 production in the presence of insulin resis-
tance [108]. 38% of APOC3 C482T and T455C variant carriers display an
increase in fasting plasma apoC3 and triglycerides in the presence of
NAFLD, compared to none in the wild-type allele carriers, as observed
in a study on Asian Indian men that was further conﬁrmed in men of
non-Asian Indian descent [109]. However, no associations between
hepatic triglyceride content and insulin resistance and the two
APOC3 variants were identiﬁed in a much larger study on multiple eth-
nic populations from theDallasHeart study and theAtherosclerosis Risk
in Communities study (ARIC) [110] and separate studies in an obese
Italian [111] and Finnish cohort [112].
2.1.9. Apolipoprotein E (ApoE)
ApoE is a major component of lipoprotein particles and its role in
the pathogenesis of NAFLD is widely accepted. Rodent studies indicate
lowered susceptibility for the development of obesity and NAFLD in the
absence of ApoE [113,114]. APOE gene has variants ε2, ε3 and ε4. The
90 A. Naik et al. / Genomics 102 (2013) 84–95occurrence of the APOE ε3 allele is signiﬁcantly higher in biopsy-proven
Caucasian NASH patients compared to controls [115], whereas the pres-
ence of the APOE ε2 allele may be protective against NAFLD [116]. How-
ever, these associations need to be conﬁrmed in larger populations of
different ethnicities.
2.1.10. Adiponectin signalling
Adiponectin (ADIPOQ) has numerous systemic protective roles,
such as insulin-sensitization, anti-inﬂammatory, anti-ﬁbrogenic and
anti-atherogenic effects, ceramide catabolism and suppression of he-
patic gluconeogenesis [39,117]. SNPs G45T and G276T of the
adiponectin gene occur at a higher incidence in an Italian NAFLD co-
hort compared to controls, together with a reduced postprandial
adiponectin response and increased postprandial plasma triglycerides,
free fatty acids and VLDL [118]. The study in Asian population did not
conﬁrm the above results [119]. Adiponectin in the liver binds to
adipoR2 receptor, which correlates negatively with insulin resistance
[120].ADIPOR2 rs767870polymorphism signiﬁcantly associateswith he-
patic lipid accumulation, as observed in a Finnish cohort and conﬁrmed
in two independent studies [121]. The presence of the C allele in the
ADIPOR2 gene correlates to a 50% decrease in hepatic fat accumulation
anda signiﬁcant decrease in serumγ-glutamyl transferase and triglycer-
ide concentrations after accounting for body mass index (BMI) [121].
2.1.11. Insulin receptor signalling
Insulin resistance is a commonly observed characteristic in NAFLD
and NASH patients. Inﬂammatory factors target insulin receptor sub-
strate (IRS) for ubiquitin-mediated degradation via activation of suppres-
sors of cytokine signalling 3 (SOCS-3), thus causing a downregulation
in insulin sensitivity [122]. NAFLD and T2D patients are usually treated
with a PPARγ-targeted thiazolidinedione, an insulin-sensitizer that re-
duces lipid release, induces lipid uptake and storage and suppresses
hepatic gluconeogenesis [123]. Polymorphisms in the plasma cell
antigen-1 (PC-1)/ectoenzyme nucleotide pyrophosphate phosphodies-
terase 1 (ENPP1) (Lys121Gln) and in IRS1 (Gly172Arg), both affecting
insulin receptor activity, are signiﬁcantly associated with NAFLD dis-
ease severity in biopsy-proven Caucasian NAFLD patients [124].
2.1.12. Growth hormone (GH) and insulin-like growth factor (IGF) axis
NAFLD and other characteristics of the metabolic syndrome are
common in patients with adult growth hormone deﬁciency (AGHD)
syndrome and hypopituitarism. GH positively regulates fatty acid oxida-
tion, lipolysis, LDL clearance and gluconeogenesis [125]. A majority
of these effects are propagated via the interaction of GH with
IGF-1, which is a catabolic hormone secreted by hepatocytes on GH-
stimulation. The bioavailability of IGF-1 is regulated by IGF-binding
protein 3 (IGFBP-3) [126]. Studies in rodents have also identiﬁed
GH-independent IGF-1 effects in improving NASH by downregulating
oxidative stress [127]. Both obese and AGHD patients with NAFLD and
insulin resistance display low levels of GH and IGF-1 and an increase
in GH-binding protein (GHBP) and IGFBP-3 that correlate with the
stage of hepatic steatosis and ﬁbrosis [128,129]. The frequency and se-
verity of fatty liver negatively correlate with GH levels in hypopituitary
males with features of the metabolic syndrome [130]. Furthermore,
GH-replacement therapy ameliorates oxidative stress in NASH patients
with AGHD [131]. Several SNPs associatedwith serum lipid proﬁleswere
identiﬁed in patients with severe AGHD and hypopituitarism in a candi-
date gene association study [132]. The G allele of PPARγwas associated
with low LDL-cholesterol. Minor alleles of rs1800775, rs708272 and
rs3764261 in the CETP gene are correlated with increased serum
HDL-cholesterol, the T allele of APOE SNP rs7412 was associated with
low total cholesterol and LDL-cholesterol and the C allele of SNP
rs35136575 in the APOE/C1/C4/C2 gene cluster was associated with in-
creased serum triglyceride levels in these patients. Although association
of these SNPs with hepatic fat content was not studied, they might rep-
resent potential candidates in the context of NAFLD development.Moreover, IGF1 and IGFBP3 polymorphisms could potentially be associat-
edwith NAFLD-related changes in IGF-1 and IGFBP-3 proteins [133,134].
2.1.13. Interleukin 6 (IL-6)
Inﬂammationis is well deﬁned as the second hit in NASH develop-
ment. Elevated IL-6 associateswith inﬂammation and insulin resistance
via proteosomal degradation of IRS-1 [122,135,136]. Circulating levels
of IL-6 are increased in individuals with T2D and obesity [136,137]. In
a Caucasian cohort the IL6-174C variant occurred at a higher frequency
in NASH than in NAFLD patients and was accompanied by increased in-
sulin resistance, in accordance with several studies that suggested the
association of theC allelewith T2D, insulin resistance and othermarkers
of the metabolic syndrome [138].
2.1.14. Drug metabolising enzymes (DMEs)
Differential expression of DMEs in NAFLD patients is mainly due
to the presence of common factors that govern lipid and xenobiotic
metabolism [139]. In healthy conditions the nuclear receptors and
phase II DMEs provide defence against hepatic oxidative stress. PXR
is a nuclear receptor that regulates the expression of several DMEs
and is also activated by endobiotics. Its activation in mice results in
hepatic steatosis [140]. rs2461823[A] and rs7643645[G]-containing
haplotypes in the PXR gene are associated with disease severity and
liver injury in a European NAFLD population [141].
The roles of GSTM, a phase II DME, and SNPs in the encoding gene
associated with NAFLD and HCC are described in Section 2.1.4. The phase
II DME UDP-glucuronosyltransferases 1A1 (UGT1A1) that protect cells
against reactive oxygen species were also candidates for genetic associ-
ation studies in an obese Taiwanese paediatric cohort, where the
UGT1A1*6 allele is associated with a lower risk of NAFLD [142]. SNPs
rs17222723 and rs8187710 in the ABC- transporter ABCC2 are associated
with NAFLD, liver histology and disease severity [143].
2.1.15. Other variant genes linked to NAFLD
Novel genetic variants were identiﬁed in association with com-
puter tomography (CT)-measured hepatic steatosis [66]. These include
neurocan (NCAN, rs2228603), the gene encoding a protein regulating
cell adhesion and migration, glucokinase regulator (GCKR, rs780094),
which inhibits glycogen synthesis, and lysophospholipase-like 1
(LYPLAL1, rs12137855) that is involved in triglyceride synthesis. These
variants display association patterns with histologic NAFLD, serum
lipids and glycaemic and anthropometric traits. A GWAS in adolescents
diagnosed with NAFLD identiﬁed SNP associations to two liver-speciﬁc
genes (the group-speciﬁc component (GC, rs222054) and lymphocyte
cytosolic protein 1 (LCP1, rs7324845)), two neuron-speciﬁc genes
(lipid phosphatase-related protein type 4 (LPPR4, rs12743824)) and a
solute carrier family 38 member 8 (SLC38A8, rs11864146). This study
further conﬁrmed the signiﬁcant differential expression of GC and
LCP1 in a NAFLD cohort [144]. Further functional characterisation of
proteins encoded by these genes is required to dissect their molecular
role in NAFLD pathogenesis.
3. Conclusion and future directions
The multi-faceted, complex, non-Mendelian nature of NAFLD and
HCC shows the heterogeneous nature of the disease in terms of disease
progression, severity, susceptibility in different ethnic populations and
treatment responses. Although GWAS and candidate gene approaches
identiﬁed several susceptibility factors associated with NAFLD, only a
few (in the case of NAFLD only PNPLA3) have been conﬁrmed in multi-
ple populations. Most studies suffer from lack of statistical power, repli-
cation in different populations, well-matched samples and the presence
of heterogeneities in disease stages. Non-additive effects, such as dom-
inance, epistasis, environmental and lifestyle factors, hinder identiﬁca-
tion of genes associated with NAFLD pathogenesis. As the invasive
liver biopsy technique remains the gold standard to diagnose NASH, a
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the disease stage which lacks accuracy due to its inability to separate
steatosis from early stages of NASH. Large-scale inter-protocol agree-
ments and standardization of grading criteria for different stages of
liver diseases are needed to reduce the current technical variability
[145]. Further development of combined polymorphism risk-scoring
algorithms, in combination with whole genome sequencing, could en-
able identiﬁcation of high risk groups for preventative care and early
detection of the disease.3.1. A future perspective: Disrupted circadian clock is another factor of
liver diseases
Awide array of physiological processes exhibit a circadian (~24 h)
rhythm represented by transcriptional and translational feedback
loops that govern internal clocks. In the liver, the circadian rhythm
results from an interplay of cis-regulatory elements [146]. Consequent-
ly, it is believed that the intrinsic gene regulatory networks determine
the hepatic clock, whereas systemic cues, such as light–dark cycles,
serve only to ﬁne-tune the rhythm. Several circadian transcription fac-
tors that can switch the gene expression on and off have been identiﬁed
but knowledge regarding global changes of rhythmic transcription at
the genome level is only starting to be revealed [147]. Circadian pro-
cesses at the body level include the sleep/wake cycle, body tempera-
ture, blood pressure, hormone secretion, etc. In the liver, the crucial
endogenous metabolic pathways (metabolism of glucose, fatty acids,
cholesterol, amino acids, etc.) and detoxiﬁcation of xenobiotics repre-
sent thousands of genes that are orchestrated by themolecular circadian
clock [147–149]. The concentration of several bloodmetabolites, includ-
ing cholesterol [150] and corticosterone [151], the mouse analogue of
cortisol, changes over 24-hour periods. It is thus not surprising than an
intact circadian clock is essential for themaintenance of body homeosta-
sis [149] and that disruption of the clock leads to desynchronization of
metabolism and consequently to pathologies, including obesity and can-
cer [152]. Furthermore, clock genes have been identiﬁed as potential
therapeutic targets. A small molecule KL001 binds to CRY1 and prevents
its degradation, resulting in lengthening of the circadian period. Stabili-
zation of CRY has important metabolic consequences since it inhibits
hepatic gluconeogenesis [153].
The major causes of clock disruption are chronic lifestyle distur-
bances, such as professional jet lag or long-term shift work. Here,
humans and mice seem to share similar mechanisms since circadian
desynchrony also promotes metabolic disruption in a mouse model
of shift work [154], where Per1 and Per2 regulate the physiological
response of metabolism associated genes to sleep disruption [155].
As relations between the hepatic clock and metabolic disturbances
may be difﬁcult to assess in humans, mousemodels remain important
tools [156–160]. Animals with mutations in clock genes have provided
key insights into the inter-dependence between the circadian clock
and metabolism [161]. One of the most striking proofs of the essential
connection between clock and metabolism in humans arises from a
14-year prospective study in Japan in which about 7000 steel industry
workers were routinely examined for general health and blood lipid pa-
rameters. The study established the adverse effects of alternating shift
work on lipid metabolism, leading to a statistically signiﬁcant rise in
total blood cholesterol [162]. The consequences of the clock disruption
for gut systems diseases, including the effect on the liver, have also
been reviewed [163] but a direct link between clock disruption and
liver diseases has been shown only in mouse models. Hepatic ﬁbrosis
in mice leads to alterations in the circadian rhythm of hepatic clock
genes where the daily rhythm of Cry2 was markedly decreased and
associated with loss of circadian rhythm of Ppara and cytochrome P450
reductase Por [164]. Moreover, the circadian disruption accelerated
hepatic carcinogenesis in mice, suggesting that persistent circadian
coordination can slow down and/or revert cancer development [165].In addition to circadian disruption, mutations in the core clock
genes might also result in disease susceptibility and progression, or
inﬂuence treatment outcomes. Hawkins et al. [166] discovered con-
siderable differences in minor allele frequency across ethnic groups
for nonsynonymous coding variants in clock genes PER1, PER2, PER3,
CLOCK and TIMELESS. Due to limitations of this study (only 95 subjects
of various ethnic groups) the link to disease could not be dissected. In
another study, a functional polymorphism in PER3, a circadian repressor,
is associated with the prognosis of HCC patients treated with trans-
catheter arterial chemoembolization. Patients carrying at least one variant
allele of rs2640908 had a signiﬁcantly lower risk of deathwhen compared
with homozygouswild-type allele patients [167]. Another study reported
the link between common genetic variations of the CLOCK gene and sus-
ceptibility to NAFLD [168]. The study included 136 patients with NAFLD
and 64 healthy individuals and showed that CLOCK variant haplotype
frequencies signiﬁcantly differ between NAFLD patients and controls.
Novel indications point to histone modiﬁcation enzymes as addi-
tional gene targets associated with circadian rhythm-related disorders.
Circadianmodiﬁcation of histone regions in daily-activated genes high-
lights epigenetic modiﬁcation as a key node regulated by the clock. The
histone-remodelling enzymeMLL3was found tomodulate hundreds of
epigenetically targeted liver circadian “output” genes, especially these
in the one-carbon metabolism pathway [147].MLL3 is thus a good can-
didate linking the circadian clock and liver diseases. It is plausible to be-
lieve that other circadian rhythm-related genes and metabolites might
in the future become recognized as promising non-invasive markers
that would be useful in determining the stages and prognosis of liver
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